5 results about "Epirubicin" patented technology

The application belongs to the field of medicine synthesis, and particularly relates to a chemical synthesis method of an epirubicin intermediate, daunorubicin. The daunorubicin is synthesized by taking 2,5-dihydroxybenzyl alcohol as raw material, the route has low raw material cost, mild reaction condition, convenient post-treatment, high total yield, and has a good industrial application prospect.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

Provided is a novel crystallization method for epirubicin hydrochloride. Provided is a production method for crystals of epirubicin hydrochloride that includes (a) a step for obtaining a mixture that includes epirubicin hydrochloride, two alcohols, and water and (b) a step for adding an ether to the mixture obtained at step (a) and crystallizing the epirubicin hydrochloride. Also provided are novel crystals of epirubicin hydrochloride.

This invention provides a novel crystallization method for epirubicin hydrochloride. [Solution] A method for producing epirubicin hydrochloride crystals is provided, comprising the steps of (a) obtaining a mixture containing epirubicin hydrochloride, two types of alcohol, and water, and (b) adding ether to the mixture obtained in step (a) to crystallize the epirubicin hydrochloride. A novel crystal of epirubicin hydrochloride is also provided.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.